MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
Portfolio Pulse from Lara Goldstein
MindMed's Phase 2b clinical trial on LSD compound MM-120 for Generalized Anxiety Disorder (GAD) treatment has enrolled and dosed over 50% of its participants. The company expects to announce topline results of the study in late 2023.
May 19, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MindMed's progress in its Phase 2b clinical trial on MM-120 for GAD treatment may positively impact its stock price.
The progress in MindMed's Phase 2b clinical trial on MM-120 for GAD treatment indicates that the company is advancing in its research and development efforts. This may lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100